Advertisement
Advertisement
U.S. markets close in 3 hours 4 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Kintara Therapeutics, Inc. (KTRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1114-0.0007 (-0.62%)
As of 12:53PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Bollinger Bands

Bollinger Bands

Previous Close0.1121
Open0.1165
Bid0.1102 x 1100
Ask0.1127 x 1800
Day's Range0.1099 - 0.1165
52 Week Range0.1050 - 1.1000
Volume429,190
Avg. Volume2,320,084
Market Cap7.482M
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-0.6430
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KTRA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kintara Therapeutics, Inc.
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID stocks) have underperformed large-caps over the past 12 months, but still may be in a better position to generate market-beating returns going forward. For one thing, SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from the Russian invasion of Ukraine. As well, the prices of SMID stocks generally are lower than the prices of large-caps. SMID stocks can be risky -- and large-caps outperformed SMID stocks in 11 of the 19 years in our test period. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 12%-15% of the U.S. stock market's capitalization is comprised of SMID stocks. For our purposes, we use a threshold of $20 billion to define a SMID stock.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
Advertisement
Advertisement